Ftse Mib
34.657,35
0,93%
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
NASDAQ
16.340,87
-0,03%
Bitcoin
60.782,00
-0,02%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Regeneron Pharmaceuticals Inc (REGN) Regeneron Pharmaceuticals Inc (REGN) Notizie

REGN

Regeneron Pharmaceuticals (REGN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:REGN
DataOraFonteTitoloSimboloCompagnia
08/05/202412:00GlobeNewswire Inc.Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 WeeksNASDAQ:REGNRegeneron Pharmaceuticals Inc
06/05/202422:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
06/05/202422:05GlobeNewswire Inc.Regeneron Announces Investor Conference PresentationsNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/05/202412:30GlobeNewswire Inc.Regeneron Reports First Quarter 2024 Financial and Operating ResultsNASDAQ:REGNRegeneron Pharmaceuticals Inc
29/04/202413:00GlobeNewswire Inc.EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal DiseasesNASDAQ:REGNRegeneron Pharmaceuticals Inc
25/04/202413:00GlobeNewswire Inc.Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple DiseasesNASDAQ:REGNRegeneron Pharmaceuticals Inc
24/04/202416:05GlobeNewswire Inc.Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCONASDAQ:REGNRegeneron Pharmaceuticals Inc
22/04/202423:54GlobeNewswire Inc.Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)NASDAQ:REGNRegeneron Pharmaceuticals Inc
16/04/202413:18IH Market NewsEricsson Soars with 66% Net Profit Growth; Live Nation Under Antitrust Scrutiny in US, and More NewsNASDAQ:REGNRegeneron Pharmaceuticals Inc
11/04/202413:24IH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/04/202422:00GlobeNewswire Inc.Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple MyelomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
01/04/202422:05GlobeNewswire Inc.Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024NASDAQ:REGNRegeneron Pharmaceuticals Inc
25/03/202412:00GlobeNewswire Inc.Regeneron Provides Update on Biologics License Application for OdronextamabNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/03/202404:55PR Newswire (US)High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical OptimizationNASDAQ:REGNRegeneron Pharmaceuticals Inc
11/03/202412:00GlobeNewswire Inc.Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High CholesterolNASDAQ:REGNRegeneron Pharmaceuticals Inc
08/03/202413:00GlobeNewswire Inc.EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The LancetNASDAQ:REGNRegeneron Pharmaceuticals Inc
01/03/202422:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
23/02/202407:00GlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 InflammationNASDAQ:REGNRegeneron Pharmaceuticals Inc
21/02/202413:00GlobeNewswire Inc.Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority ReviewNASDAQ:REGNRegeneron Pharmaceuticals Inc
16/02/202406:59GlobeNewswire Inc.Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)NASDAQ:REGNRegeneron Pharmaceuticals Inc
10/02/202400:19Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:REGNRegeneron Pharmaceuticals Inc
08/02/202422:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
05/02/202415:16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:REGNRegeneron Pharmaceuticals Inc
02/02/202413:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/02/202412:30GlobeNewswire Inc.Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating ResultsNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/02/202412:00GlobeNewswire Inc.Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple MyelomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
30/01/202415:25AllPennyStocks.comBiotech Shares Soar Premarket On Sale Of R&D AssetsNASDAQ:REGNRegeneron Pharmaceuticals Inc
30/01/202413:00GlobeNewswire Inc.Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical ProgramsNASDAQ:REGNRegeneron Pharmaceuticals Inc
25/01/202420:29GlobeNewswire Inc.Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)NASDAQ:REGNRegeneron Pharmaceuticals Inc
24/01/202418:05PR Newswire (US)Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in AwardsNASDAQ:REGNRegeneron Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:REGN

La tua Cronologia

BIT
ENEL
Enel
BIT
UCG
Unicredit
BIT
BFF
BFF Bank
BIT
ISP
Intesa Sanpaolo
BIT
LDO
Leonardo
BIT
IVG
Iveco Group NV
BIT
RACE
Ferrari NV
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
NEXI
Nexi S.p.A
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
MB
Mediobanca Banca di Cred...
BIT
PRY
Prysmian
BIT
STMMI
ST Microelectronics
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network